The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2019 | Myeloma prognosis – the emergence of MRD
Bruno Paiva
• 12 Sep 2019
Bruno Paiva, PhD from the University of Navarra Clinic, Pamplona, Spain, describes the emergence of measurable residual disease (MRD) in determining the prognosis of multiple myeloma. Dr Paiva was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
